Viloxazine HCl is a selective norepinephrine reuptake inhibitor indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age.
Viloxazine
Specifications
Human
Oral
In Development
FEATURED Products
Related Media
New Product Development
Where our FDA approved laboratory begins developing products, formulating and validating methods to ensure quality.
Compliance Audits
Where we audit and champion our partner factories to exceed cGMP standards set by authorities.
Regulatory Services
Where all submissions are filed with the knowledge and experience of our 550+ worldwide approvals on record.